Rheumatic diseases
Conditions
Interventions
Aminovalue conc 2 bottles after each meal, everyday, for 3 months
Control
Sponsors
IMSUT Hospital, Institute of Medical Science, University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patints who visit IMSUT Hospital 2. Patients who give a written informed consent 3. At the time of informed consent, patients take and will take prednisolone (>10mg/day) for at least consecutive 3 months.
Exclusion criteria
Exclusion criteria: Severe kidney dysfunction Severe proteinuria Severe diabetes Hematopoietic disorders Severe hepatic dysfunction Congenital abnormality in amino acid metabolism Severe heart diseases Patients with artificial ventilation patients with severe infection patients who are recruited or was recruited (within 1 month) in other clinical trials Pregnancy, breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of muscle mass and function using manual muscle test, bioimpedance, X-ray CT, and MRI imaging. | — |
Secondary
| Measure | Time frame |
|---|---|
| Performance Status, evaluation of daily living activity,squatting Blood and urine biochemistry | — |
Countries
Japan
Contacts
Public ContactNoritada Yoshikawa
IMSUT Hospital, Institute of Medical Science, University of Tokyo Department of Allergy and Rheumatology
Outcome results
None listed